Last reviewed 2026-04-22 · How we verify

Thrombin JMI

Thrombin JMI is a topical thrombin preparation that directly converts fibrinogen to fibrin to promote blood clotting and hemostasis at wound sites.

Thrombin JMI is a topical thrombin preparation that directly converts fibrinogen to fibrin to promote blood clotting and hemostasis at wound sites. Used for Hemostasis in surgical procedures, Control of bleeding in general surgery, cardiac surgery, and vascular surgery.

At a glance

Mechanism of action

Thrombin JMI is a serine protease derived from bovine sources that catalyzes the final step of the coagulation cascade by cleaving fibrinogen into fibrin monomers, which polymerize to form a stable clot. It is applied topically to surgical wounds and bleeding sites to achieve rapid hemostasis without requiring the upstream coagulation cascade. This allows for immediate clot formation at the site of application.

Approved indications

• Hemostasis in surgical procedures
• Control of bleeding in general surgery, cardiac surgery, and vascular surgery

Common side effects

• Thrombosis (when absorbed systemically)
• Allergic reaction
• Fever

Key clinical trials

• Goal-Directed Hemostatic Resuscitation Trial in ACLF Induced Coagulopathy (NA)
• Monitoring of Anti-TFPI in Hemophilia
• Efficacy of Platelet-rich-Fibrin Gel in Patients With Chronic Leg Ulcers (EARLY_PHASE1)
• Testing a New Treatment Strategy to Improve Secondary Stroke Prevention for Older Adults: The STROKE75+ Trial (PHASE3)
• A Trial of Intraoperative Fibrin Sealant on Postoperative Recovery After Total Knee Replacement (PHASE4)
• Study of Hemostasis in Patients With Congenital Disorder of Glycosylation
• GATT-Patch Versus TachoSil in Liver Surgery (NA)
• SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.